Related references
Note: Only part of the references are listed.GRP75 as a functional element of cholix transcytosis
Keyi Liu et al.
TISSUE BARRIERS (2023)
Oral delivery of systemic monoclonal antibodies, peptides and small molecules using gastric auto-injectors
Alex Abramson et al.
NATURE BIOTECHNOLOGY (2022)
Inhomogeneous Diastereomeric Composition of Mongersen Antisense Phosphorothioate Oligonucleotide Preparations and Related Pharmacological Activity Impairment
Lorenzo Arrico et al.
NUCLEIC ACID THERAPEUTICS (2022)
Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
Giovanni Monteleone et al.
MOLECULAR DIAGNOSIS & THERAPY (2022)
Ozanimod as a novel oral small molecule therapy for the treatment of Crohn's disease: The YELLOWSTONE clinical trial program
Brian G. Feagan et al.
CONTEMPORARY CLINICAL TRIALS (2022)
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis Results From a Phase 2a Clinical Trial
Einat Almon et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2021)
S785 Alicaforsen Enema in Chronic Pouchitis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Trial
Brian Feagan et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)
Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
David S. Weinberg et al.
CANCER BIOLOGY & THERAPY (2021)
The Era of Janus Kinase Inhibitors for Inflammatory Bowel Disease Treatment
Jin-Woo Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors
Thomas J. Tucker et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease
Kevin J. Roberts et al.
SCIENTIFIC REPORTS (2021)
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn's Disease: A Phase II, Open-Label Study
Irene Marafini et al.
BIODRUGS (2021)
How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions
Piotr Eder et al.
JOURNAL OF NANOBIOTECHNOLOGY (2021)
Improving the Gastrointestinal Stability of Linaclotide
Nayara Braga Emidio et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
An oral antisense oligonucleotide for PCSK9 inhibition
Peter Gennemark et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Single- and Multiple-Dose Pharmacokinetics and Pharmacodynamics of PN-943, a Gastrointestinal-Restricted Oral Peptide Antagonist of α4β7, in Healthy Volunteers
Nishit B. Modi et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2021)
Oral delivery of proteins and peptides: Challenges, status quo and future perspectives
Quangang Zhu et al.
ACTA PHARMACEUTICA SINICA B (2021)
Anti-integrin drugs in clinical trials for inflammatory bowel disease (IBD): insights into promising agents
Virginia Solitano et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)
PTG-100, an Oral α4β7 Antagonist Peptide: Preclinical Development and Phase 1 and 2a Studies in Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2021)
Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery
Randall J. Mrsny et al.
PHARMACEUTICS (2021)
Oral Delivery of Biologics in Inflammatory Bowel Disease Treatment
Wunan Zhang et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2021)
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study
Bruce E. Sands et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Advances in oral peptide therapeutics
Daniel J. Drucker
NATURE REVIEWS DRUG DISCOVERY (2020)
Systemic delivery of peptides by the oral route: Formulation and medicinal chemistry approaches
D. J. Brayden et al.
ADVANCED DRUG DELIVERY REVIEWS (2020)
Small molecule drugs in the treatment of inflammatory bowel diseases: which one, when and why? - a systematic review
Laura A. Lucaciu et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2020)
Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease
Yunyue Zhang et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Kateryna Pierzynowska et al.
FRONTIERS IN MEDICINE (2020)
A Novel Fusion of IL-10 Engineered to Traffic across Intestinal Epithelium to Treat Colitis
Nicole C. Fay et al.
JOURNAL OF IMMUNOLOGY (2020)
Cholix protein domain I functions as a carrier element for efficient apical to basal epithelial transcytosis
Alistair Taverner et al.
TISSUE BARRIERS (2020)
416 – The Oral Α4Β7 Integrin Specific Antagonist Pn-10943 is More Effective Than Ptg-100 in Multiple Preclinical Studies
Larry Mattheakis et al.
GASTROENTEROLOGY (2019)
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
Suhail Nurbhai et al.
SCIENTIFIC REPORTS (2019)
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys
J. Scott Crowe et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2019)
Probing the Role of Melanocortin Type 1 Receptor Agonists in Diverse Immunological Diseases
Carl Spana et al.
FRONTIERS IN PHARMACOLOGY (2019)
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis
Elisa K. Boden et al.
CROHNS & COLITIS 360 (2019)
Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders
Scott A. Waldman et al.
GUT (2018)
Targeting Endothelial Ligands: ICAM-1/alicaforsen, MAdCAM-1
Walter Reinisch et al.
JOURNAL OF CROHNS & COLITIS (2018)
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
J. Scott Crowe et al.
SCIENTIFIC REPORTS (2018)
Local delivery of macromolecules to treat diseases associated with the colon
A. Bak et al.
ADVANCED DRUG DELIVERY REVIEWS (2018)
Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
Stephen T. Buckley et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation
Satish S. C. Rao
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis
Yaron Ilan et al.
IMMUNOBIOLOGY (2017)
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease
Maria Rosario et al.
JOURNAL OF CROHNS & COLITIS (2017)
An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy
Einat Almon et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2017)
Oral delivery of macromolecular drugs: Where we are after almost 100 years of attempts
Elena Moroz et al.
ADVANCED DRUG DELIVERY REVIEWS (2016)
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis
Deborah S. Hartman et al.
JOURNAL OF CROHNS & COLITIS (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
Yaron Ilan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
A Multihit Model: Colitis Lessons from the Interleukin-10-deficient Mouse
Lydia M. Keubler et al.
INFLAMMATORY BOWEL DISEASES (2015)
Review article: linaclotide for the management of irritable bowel syndrome with constipation
P. Layer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
A review of the clinical efficacy of linaclotide in irritable bowel syndrome with constipation
Jeffrey M. Johnston et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease
Kailash C. Bhol et al.
INFLAMMATORY BOWEL DISEASES (2013)
An Oral CD3-Specific Antibody Suppresses T-Cell-Induced Colitis and Alters Cytokine Responses to T-Cell Activation in Mice
Katharina Forster et al.
GASTROENTEROLOGY (2012)
Oral Octreotide Absorption in Human Subjects: Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression
S. Tuvia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis
Monica Boirivant et al.
GASTROENTEROLOGY (2006)
Crucial role of the melanocortin receptor MC1R in experimental colitis
C. Maaser et al.
GUT (2006)
A phase I trial with Transgenic bacteria expressing interleukin-10 in Crohn's disease
Henri Braat et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate
AA Raoof et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10
L Steidler et al.
SCIENCE (2000)
Share Paper
